# ReSPECT-GBM (NCT01906385)

> Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01906385
- Phase: PHASE1, PHASE2
- Status: RECRUITING
- Sponsor: Cerenome
- Conditions: Glioma
- Interventions: Rhenium Liposome Treatment
- Enrollment: 55
- Primary outcome: Phase 1: Maximum Tolerated Dose
- Primary outcome: Phase 2: Overall Survival

## Indexed commentary on ReSPECT-GBM so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=respect-gbm-nct01906385